|Bid||2.2800 x 1400|
|Ask||2.3700 x 1200|
|Day's range||2.2550 - 2.5699|
|52-week range||2.2000 - 10.8800|
|Beta (5Y monthly)||2.41|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
DiaMedica (DMAC) is developing its recombinant KLK1 protein candidate, DM199 for treating patients who suffered an acute ischemic stroke in the last 24 hours as well as for reducing the risk of recurrent stroke.
DiaMedica Therapeutics (DMAC) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.
Investors need to pay close attention to DiaMedica (DMAC) stock based on the movements in the options market lately.